ArticleBMC cancer2025
Using single-cell and transcriptome data to identify prognostic genes associated with SUMO-ylation and their molecular regulatory mechanisms in breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDysregulation of small ubiquitin-like modifier ylation (SUMO-ylation) is closely associated with the development of different types of cancers. Growing evidence indicates that many SUMOylated genes (SRGs) play a role in the initiation and progression of breast cancer (BRCA). However, its prognostic value in BRCA remains inadequately explored.
methodsThis study explored prognostic genes related to SUMO-ylation in BRCA based on single-cell RNA sequencing (scRNA-seq) and transcriptome data, developed and validated a risk model. Furthermore, an analysis of clinical relevance was performed to determine independent prognostic factors associated with BRCA. Additionally, enrichment analysis, immune analysis, drug sensitivity analysis, and construction of molecular regulatory networks were executed to probe the potential molecular mechanisms of prognostic genes. Communication analysis and pseudo-time analysis of the prognostic genes were also conducted at the scRNA-seq level to further investigate cell interactions and differentiation trajectories of different cell subtypes. Finally, reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) was performed to validate the expression of the prognostic genes in BRCA and paracancerous tissues.
resultsBased on a series of analyses, 8 prognostic genes were identified, namely GPC1, CAPZA1, NUDCD1, MTDH, COX7A1, PLK3, FAM43A, and CEBPD. The risk model developed from these prognostic genes demonstrated good performance and broad applicability with area under the curve (AUC) values of 0.716, 0.677 and 0.657 at 1, 3, 5 years, respectively. The nomogram model constructed by combining the risk scores obtained from the above risk model with age, N-stage, and radiotherapy also has predictive ability, with AUC values exceeding 0.7 at all three time points. Furthermore, immune analysis identified the different infiltration proportions of CD8 T cells, NK cells, resting dendritic cells and M2 macrophages between high- and low-risk cohorts. IC
conclusionsIn this study, 8 SUMO-ylation related prognostic genes were identified in BRCA, namely GPC1, CAPZA1, NUDCD1, MTDH, COX7A1, PLK3, FAM43A and CEBPD, offering fresh perspectives on the prognosis of BRCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.